Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments

Progress of Conductivity and Conduction Velocity Measured in Human and Animal Hearts

Mechanistic and Therapeutic Perspectives for Cardiac Arrhythmias: Beyond Ion Channels

Insights into Cardiac Conduction System Formation Provided by HCN4 Expression.

Ultrastructure and cardiac impulse propagation: scaling up from microscopic to macroscopic conduction

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Molecular biology of K(+) channels and their role in cardiac arrhythmias.

Remodelling of gap junctions and connexin expression in diseased myocardium

Transcriptional regulation of the postnatal cardiac conduction system heterogeneity

Systems approach to understanding electrical activity in the human heart

Molecular Regulation of Cardiac Conduction System Development

Cardiomyocyte electrophysiology and its modulation: current views and future prospects

Inherited Arrhythmias Cardiomyopathies: 2007 Advancement and Workshop Consensus

KCCs, NKCCs, and NCC: Potential targets for cardiovascular therapeutics? A comprehensive review of cell and region specific expression and function

Genetic Na+ Channelopathies and Sinus Node Dysfunction.

Genetic Abnormalities of the Sinoatrial Node and Atrioventricular Conduction

Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation

Integrated transcriptome and lineage analyses reveal novel catecholaminergic cardiomyocytes contributing to the cardiac conduction system in murine heart

The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues

Investigation Of The Functional Effects Of Kcnj2-Linked Short Qt Syndrome On Electrical Conduction At Purkinje-Ventricle Junction At Low- And High-Frequencies

Molecular Genetics of Long QT Syndrome from Genes to Patients